Guggenheim reiterated one biotech name as its top pick Wednesday after the company reported positive monotherapy data for its TL1A ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE